Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.76 |
| ▸ | KDR | P35968 | 20/20 | 0.76 |
| ▸ | AURKA | O14965 | 1/20 | 0.70 |
| ▸ | FPR1 | P21462 | 1/20 | 0.70 |
| ▸ | FPR3 | P25089 | 1/20 | 0.70 |
| ▸ | GPR183 | P32249 | 1/20 | 0.70 |
| ▸ | SMO | Q99835 | 1/20 | 0.70 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13166939 | 0.91 | MET (0.81) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL2287810 | 0.91 | MET (0.90) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL12376884 | 0.90 | MET (0.79) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3566472 | 0.89 | MET (0.82) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3570597 | 0.89 | MET (0.79) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL27885635 | 0.89 | MET (0.81) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3574341 | 0.88 | MET (0.78) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3563400 | 0.88 | MET (0.80) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL3563913 | 0.87 | MET (0.77) | METKDRAURKAFPR1FPR3 | |
| SCHEMBL2670933 | 0.87 | MET (0.73) | METKDRAURKAFPR1FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| WO-2008063202-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | MET 142/4885KDR 419/4885AURKA 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.